纵向观察研究中医务人员接种疫苗或自然感染后的SARS-CoV-2抗体应答
研究在受COVID-19疫情影响的一家二级医院员工中开展纵向观察研究,比较自然感染、接种一剂或两剂BioNTech/Pfizer(BNT162b2)疫苗、接种一剂AstraZeneca(Vaxzevria)疫苗后抗SARS-CoV-2免疫球蛋白G(IgG)抗体比值。结果显示,完成两剂BNT162b2接种者体液应答率为100%;接种一剂BNT162b2或Vaxzevria者抗体比值与既往PCR确诊感染者无显著差异,但显著低于两剂BNT162b2接种者;吸烟对抗体应答呈负面影响(p = 0.006)。
要点
- 两剂BNT162b2接种者体液应答率为100%。
- 一剂BNT162b2或Vaxzevria者抗体比值与既往PCR确诊感染者无显著差异。
- 吸烟对抗体应答呈负面影响(p = 0.006)。
核心结论
- 自然SARS-CoV-2感染或接种疫苗后的体液免疫应答数据支持使用加强针,尤其适用于自然SARS-CoV-2感染后的患者。
研究设计与样本
- 在受COVID-19疫情影响的一家二级医院员工中开展的纵向观察研究。
- 比较自然感染、接种一剂或两剂BioNTech/Pfizer(BNT162b2)疫苗、接种一剂AstraZeneca(Vaxzevria)疫苗后抗SARS-CoV-2免疫球蛋白G(IgG)抗体比值。
主要发现
- 完成两剂BNT162b2疫苗接种的参与者体液应答率为100%。
- 接种一剂BNT162b2和Vaxzevria的参与者抗体比值与既往PCR确诊感染者无显著差异。
- 接种一剂BNT162b2和Vaxzevria的参与者抗体比值显著低于接种两剂BioNTech/Pfizer者。
- 本研究未能发现抗体应答与既往合并症、肥胖或年龄的相关性。
- 吸烟对 antibody 应答呈负面影响(p = 0.006)。
临床怎么用
- 作者认为数据支持使用加强针,尤其适用于自然SARS-CoV-2感染后的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following a year of development, several vaccines have been approved to contain the global COVID-19 pandemic. Real world comparative data on immune response following vaccination or natural infection are rare. METHODS: We conducted a longitudinal observational study in employees at a secondary care hospital affected by the COVID-19 pandemic. Comparisons were made about the presence of anti-SARS-CoV-2 immunglobulin G (IgG) antibody ratio after natural infection, or vaccination with one or two doses of BioNTech/Pfizer (BNT162b2), or one dose of AstraZenca (Vaxzevria) vaccine. RESULTS: We found a 100% humoral response rate in participants after 2 doses of BNT162b2 vaccine. The antibody ratio in participants with one dose BNT162b2 and Vaxzevria did not differ significantly to those with previous PCR-confirmed infection, whereas this was significantly lower in comparison to two doses of BioNTech/Pfizer. We could not identify a correlation with previous comorbidities, obesity or age within this study. Smoking showed a negative effect on the antibody response (p = 0.006) CONCLUSION: Our data provide an overview about humoral immune response after natural SARS-CoV-2 infection or following vaccination, and supports the usage of booster vaccinations, especially in patients after a natural SARS-CoV-2 infection.
引用
- Herzberg J, Vollmer T, Fischer B, et al. SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study. Vaccine. 2021. PMID: 34895938. doi:10.1016/j.vaccine.2021.11.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。